SCHEMBL337347

SCHEMBL337347

O=C(Cl)CC1NC(=O)NC1=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.50
ALDH1A1 P00352 4/20 0.43
KMT2A Q03164 3/20 0.43
MEN1 O00255 2/20 0.43
CASP1 P29466 1/20 0.43
KDM4E B2RXH2 3/20 0.41
TSHR P16473 2/20 0.41
ADAMTS5 Q9UNA0 7/20 0.38
ADAMTS4 O75173 2/20 0.38
ADAM17 P78536 2/20 0.38
ADAM10 O14672 1/20 0.38
MMP12 P39900 1/20 0.38
ADAM9 Q13443 1/20 0.38
RGS12 O14924 1/20 0.37
MAPT P10636 2/20 0.37
NPC1 O15118 1/20 0.37
TP53 P04637 1/20 0.37
HPGD P15428 1/20 0.37
ALOX15 P16050 1/20 0.37
MAPK1 P28482 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5620774 0.81 GAA (0.56) GAAALDH1A1KMT2AMEN1CASP1
SCHEMBL2879208 0.79 ALDH1A1 (0.51) GAAALDH1A1KMT2AMEN1CASP1
SCHEMBL17969510 0.78 GAA (0.53) GAAALDH1A1KMT2AMEN1CASP1
SCHEMBL17969508 0.78 GAA (0.53) GAAALDH1A1KMT2AMEN1CASP1
SCHEMBL12344339 0.75 GAA (0.46) GAAALDH1A1KMT2AMEN1CASP1
SCHEMBL9402148 0.73 GAA (0.45) GAAALDH1A1KMT2AMEN1CASP1
SCHEMBL9402142 0.73
SCHEMBL11352404 0.72 TSHR (0.46) GAAALDH1A1KMT2AMEN1CASP1
SCHEMBL6224351 0.70 GAA (0.41) GAAALDH1A1KMT2AMEN1CASP1
SCHEMBL9402166 0.70 TSHR (0.39) GAAALDH1A1KMT2AMEN1CASP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9487494-B2 Cyclic hydrocarbon compounds for the treatment of diseases LEO PHARMA A/S (DK) 2016-11-08 US disclosed
US-8097343-B2 Functionalized dendritic polymers for the capture and neutralization of biological and chemical agents TRITON SYSTEMS, INC. (US) 2012-01-17 US disclosed
US-8034811-B2 Hydroxamic acid esters and pharmaceutical use thereof LEO PHARMA A/S (DK) 2011-10-11 US disclosed
EP-1697312-B1 HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF LEO PHARMA AS (DK) 2011-07-20 EP disclosed
US-20100317582-A1 NOVEL CYCLIC HYDROCARBON COMPOUNDS FOR THE TREATMENT OF DISEASES LEO PHARMA A/S (DK) 2010-12-16 US disclosed
EP-2234961-A2 NOVEL CYCLIC HYDROCARBON COMPOUNDS FOR THE TREATMENT OF DISEASES LEO PHARMA A/S (DK) 2010-10-06 EP disclosed
WO-2009065406-A2 NOVEL CYCLIC HYDROCARBON COMPOUNDS FOR THE TREATMENT OF DISEASES LEO PHARMA A/S (DK) 2009-05-28 WO disclosed
US-7384626-B2 Functionalized dendritic polymers for the capture and neutralization of biological and chemical agents TRITON SYSTEMS, INC. (US) 2008-06-10 US disclosed
US-20070244117-A1 Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof LEO PHARMA A/S (DK) 2007-10-18 US disclosed
US-20070071713-A1 FUNCTIONALIZED DENDRITIC POLYMERS FOR THE CAPTURE AND NEUTRALIZATION OF BIOLOGICAL AND CHEMICAL AGENTS TRITON SYSTEMS, INC. 2007-03-29 US disclosed
US-20070014754-A1 Functionalized dendritic polymers for the capture and neutralization of biological and chemical agents TRITON SYSTEMS, INC. 2007-01-18 US disclosed
WO-2006135406-A2 FUNCTIONALIZED DENDRITIC POLYMERS FOR THE CAPTURE AND NEUTRALIZATION OF BIOLOGICAL AND CHEMICAL AGENTS TRITON SYSTEMS, INC. (US) 2006-12-21 WO disclosed
EP-1697312-A2 HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF Leo Pharma A/S (DK) 2006-09-06 EP disclosed
WO-2005054179-A2 HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF LEO PHARMA A/S (DK) 2005-06-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070071713-A1 FUNCTIONALIZED DENDRITIC POLYMERS FOR THE CAPTURE AND NEUTRALIZATION OF BIOLOGICAL AND CHEMICAL AGENTS CD47, CD209, HAVCR2 GAA 760/4885ALDH1A1 3513/4885KMT2A 1665/4885
US-20100317582-A1 NOVEL CYCLIC HYDROCARBON COMPOUNDS FOR THE TREATMENT OF DISEASES ARNT, AHR, CYP27A1 GAA 1308/4885ALDH1A1 1743/4885KMT2A 2151/4885
US-20070244117-A1 Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof F9, F12, HDAC9 GAA 264/4885ALDH1A1 804/4885KMT2A 1452/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.